Yihan Li

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Double‐Blind, Randomized Controlled Trial

Roy Fleischmann, Aileen L. Pangan, In‐Ho Song et al. · Arthritis & Rheumatology · 2019 · 436 citations

Medicine, Pharmacology, Pharmacotherapy +16

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Gerd R Burmester, Joel M. Kremer, Filip Van den Bosch et al. · The Lancet · 2018 · 397 citations

Medicine, Internal Medicine, Pharmacology +13

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Roy Fleischmann, Mark C. Genovese, Jeffrey Enejosa et al. · Annals of the Rheumatic Diseases · 2019 · 174 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy et al. · The Lancet · 2022 · 135 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +3

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Roy Fleischmann, Eduardo Mysler, Louis Bessette et al. · RMD Open · 2022 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17